64 results on '"Del Vecchio M"'
Search Results
2. Biomarqueurs (BMs) associés à l’efficacité du nivolumab (NIVO) versus placebo (PBO) en adjuvant chez des patients atteints de mélanome réséqué de stade IIB/C (CA209-76K)
3. Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology
4. Italian Nivolumab Expanded Access Program (EAP) in Melanoma Adjuvant Setting: patient outcomes and safety profil
5. 89P Impact of metformin on glucocorticoid-induced changes in systemic metabolism in patients with brain metastases from solid malignancies
6. Survie sans métastases à distance avec pembrolizumab versus placebo en traitement adjuvant du mélanome de stade IIB ou IIC : étude de phase III KEYNOTE-716
7. 803P Patient-reported outcomes in patients with resected, stage III BRAF V600+ melanoma treated with adjuvant dabrafenib + trametinib: COMBI-APlus study
8. 788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)
9. 806P Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus
10. Simultaneous stereo-EEG and high-density scalp EEG recordings to study the effects of intracerebral stimulation parameters
11. LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
12. LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial
13. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
14. Nivolumab (NIVO) vs ipilimumab (IPI) en traitement adjuvant du mélanome de stade III/IV opéré : résultats de survie sans récidive (SSR) et de survie globale (SG) à 4 ans de l’essai CheckMate 238
15. 1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
16. 1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
17. LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)
18. Anticancer innovative therapy: Highlights from the ninth annual meeting
19. Nivolumab (NIVO) versus ipilimumab (IPI) dans le traitement adjuvant du mélanome réséqué de stade III/IV: résultats d’efficacité à 3 ans et analyse de biomarqueurs issus de l’essai de phase 3 CheckMate 238
20. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
21. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting
22. Traitement adjuvant par nivolumab (NIVO) par rapport à l’ipilimumab (IPI) après résection complète d’un mélanome au stade III/IV : résultats actualisés d’un essai de phase III (CheckMate 238)
23. KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
24. Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?
25. PCN111 - COST ESTIMATE OF IMMUNE-RELATED ADVERSE REACTIONS ASSOCIATED WITH INNOVATIVE TREATMENTS OF METASTATIC MELANOMA
26. Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
27. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
28. Combination of brain radiotherapy (RT) and immunotherapy (IT) in a single Institution cohort of patients (pts) with metastatic melanoma (MM)
29. Innovative Therapy, Monoclonal Antibodies and Beyond
30. Brain radiotherapy (RT) and immunotherapy (IT) for metastatic melanoma (MM): a retrospective single institution experience
31. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)
32. 409P CARAMEL study: ClinicAl prognostic biomarkers for Ipilimumab-Related outcome in metastatic MELanoma patients
33. Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?
34. Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)
35. CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients
36. Monoinstitutional experience of vemurafenib and cobimetinib for BRAF mutated metastatic melanoma
37. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
38. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
39. Design of a new experimental facility to reproduce LOVA and LOCA consequences on dust resuspension
40. Disthyroidism during immune checkpoints inhibitors treatment: toxicity or something more?
41. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
42. Shadowgraph Technique Applied to STARDUST Facility for Dust Tracking: First Results
43. Vemurafenib in Brafv600 Mutated Metastatic Melanoma (Mm): a Subanalysis of the Italian Population of a Global Safety Study
44. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
45. The European Ipilimumab Expanded Access Programme (EAP): Efficacy and Safety Data from the Italian Cohort of Patients with Pretreated, Advanced Melanoma
46. Efficacy and Safety of Ipilimumab in Patients with Pretreated, Mucosal Melanoma: Experience from Italian Clinics Participating in the European Expanded Access Programme (EAP)
47. Efficacy and Safety of Ipilimumab Reinduction Therapy Patients with Pretreated Advanced Melanoma Participating in an Expanded Access Programme (EAP) in Italy
48. An Open-Label, Multicentre Safety Study of Vemurafenib in Patients with Metastatic Melanoma
49. 9328 The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients
50. Acute pancreatitis in a girl with panhypopituitarism secondary to resection of craniopharyngioma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.